Tatiana Malishevskaya

Prof. Tatiana Malishevskaya

Helmholtz Moscow Research Institute of Eye Diseases, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
Denis GubinDenis Gubin
Denis Gubin
TMTatiana Malishevskaya
Tatiana Malishevskaya
DWDietmar Weinert
Dietmar Weinert
EZEkaterina Zakharova
Ekaterina Zakharova
SASergey Astakhov
Sergey Astakhov
GERMAINE CORNELISSENGERMAINE CORNELISSEN
GERMAINE CORNELISSEN
This review explores the intricate relationship between glaucoma and circadian rhythm disturbances. As a principal organ for photic signal reception and transduction, the eye plays a pivotal role in coordinating the body's circadian rhythms through specialized retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs). These cells are critical in transmitting light signals to the suprachiasmatic nucleus (SCN), the central circadian clock that synchronizes physiological processes to the 24-hour light-dark cycle. The review delves into the central circadian body clock, highlighting the importance of the retino-hypothalamic tract in conveying light information from the eyes to the SCN. It underscores the role of melanopsin in ipRGCs in absorbing light and initiating biochemical reactions that culminate in the synchronization of the SCN's firing patterns with the external environment. Furthermore, the review discusses local circadian rhythms within the eye, such as those affecting photoreceptor sensitivity, corneal thickness, and intraocular fluid outflow. It emphasizes the potential of optical coherence tomography (OCT) in studying structural losses of RGCs in glaucoma and the associated circadian rhythm disruption. Glaucomatous retinal damage is identified as a cause of circadian disruption, with mechanisms including oxidative stress, neuroinflammation, and direct damage to RGCs. The consequences of such disruption are complex, affecting systemic and local circadian rhythms, sleep patterns, mood, and metabolism. Countermeasures, with implications for glaucoma management, are proposed that focus on strategies to improve circadian health through balanced melatonin timing, daylight exposure, and potential chronotherapeutic approaches. The review calls for further research to elucidate the mechanisms linking glaucoma and circadian disruption and to develop effective interventions to address this critical aspect of the disease.

1 October 2024 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
VNV. V. Neroev
V. V. Neroev
LML. A. Mikhaylova
L. A. Mikhaylova
TMTatiana Malishevskaya
Tatiana Malishevskaya
SPSergey Petrov
Sergey Petrov
OFO. M. Filippova
O. M. Filippova
Glaucoma is worldwide the most common cause of irreversible blindness. Its prevalence in the population older than 40 years is about 3.5 %, and correlates with age. The most common type is primary open-angle glaucoma (POAG). The global prevalence of POAG is expected to grow from 76.0 million in 2020 to 111.8 million by 2040. In 2022, a total of 1,250,558 patients with glaucoma were registered in the Russian Federation, of which 110,680 had newly diagnosed glaucoma. The overall glaucoma incidence rate in Russia shows a steady growth: in 2022, it increased by 30 % as compared to 2013. In order to meet the challenge, medical care of glaucomatous patients is on the rise: the contingent receiving dispensary observation increased by 6.8 % over the last 10 years, whilst surgical treatment involved 28.1 % more patients.

23 June 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Denis GubinDenis Gubin
Denis Gubin
VNVladimir Neroev
Vladimir Neroev
TMTatiana Malishevskaya
Tatiana Malishevskaya
SKSergey N Kolomeichuk
Sergey N Kolomeichuk
DWDietmar Weinert
Dietmar Weinert
GERMAINE CORNELISSENGERMAINE CORNELISSEN
GERMAINE CORNELISSEN
Lipid metabolism is intimately linked to circadian mechanisms and light signaling. Deteriorated photic transduction because of retinal ganglion cell (RGC) loss occurring with glaucoma progression reduces perceived light amplitude, causing circadian disruption. To investigate associations with RGCs, total cholesterol (TC), its low-density (LDL-C) and high-density (HDL-C) fractions, and triglycerides (TG) were measured, under a controlled meal regimen, during daytime hours in 114 patients diagnosed with primary open-angle glaucoma (POAG). RGC damage was assessed by high-definition optical coherence tomography (HD-OCT). Analysis of eight clock, clock-related, and melatonin receptor gene polymorphisms was performed on 19 patients. RGC loss was associated with changes in lipid metabolism in a time-dependent manner. Morning (08:00) values of HDL-C (r = 0.613, p < 0.0001) and TG (r = 0.568, p < 0.0001) correlated positively with RGC global loss, while LDL-C at 08:00 had a weak correlation (r = 0.235; p = 0.012) but showed a strong correlation in the evening (20:00) (r = 0.533, p < 0.0001). The morning–evening gradients (MEGs, changes at 20:00 versus 08:00) in TC and LDL-C changed sign from a negative to a positive association in patients exceeding the 15% two-eye mean GLV threshold. MEG (LDL-C higher in the evening than in the morning) was positive only in POAG patients with the CLOCK_3111 TT genotype.

Verified
Journal Article
Open access
PDF file
VNVladimir Neroev
Vladimir Neroev
TMTatiana Malishevskaya
Tatiana Malishevskaya
DWDietmar Weinert
Dietmar Weinert
SASergei Astakhov
Sergei Astakhov
SKSergey N Kolomeichuk
Sergey N Kolomeichuk
Denis GubinDenis Gubin
Denis Gubin
Parameters of 24-h rhythm in intraocular pressure (IOP) were assessed in patients with stable or advanced primary open-angle glaucoma (S-POAG/A-POAG) and referenced to the phase of “marker” circadian temperature rhythm of each patient. Body temperature and IOP were measured over a 72-h span in 115 participants (65 S-POAG and 50 A-POAG). Retinal Ganglion Cell (RGC) damage was assessed by high-definition optical coherence tomography. The 24-h IOP rhythm in A-POAG patients peaked during the night, opposite to the daytime phase position in S-POAG patients (p < 0.0001). The 24-h IOP phase correlated with RGC loss (p < 0.0001). The internal phase shift between IOP and body temperature gradually increased with POAG progression (p < 0.001). Angiotensin converting enzyme Alu-repeat deletion/insertion (ACE I/D) emerged as a candidate gene polymorphism, which may play a role in the alteration of the circadian IOP variability in advanced glaucoma. To conclude, a reliable estimation of the 24-h rhythm in IOP requires the degree of RGC damage to be assessed. In advanced POAG, the 24-h phase of IOP tended to occur during the night and correlated with RGC loss, being progressively delayed relative to the phase of temperature.

28 August 2023 in Russian Annals of Ophthalmology
Verified
Journal Article
Closed access
TMTatiana Malishevskaya
Tatiana Malishevskaya
YFYu.E. Filippova
Yu.E. Filippova
У пациентов с глаукомой одним из основных инициирующих механизмов, запускающих цепь событий, является нарушение универсального механизма регулирования сосудистого тонуса вследствие эндотелиальной дисфункции (ЭД). Основным проявлением ЭД служит дисбаланс вазоконстрикторных и вазодилататорных эндотелиальных медиаторов, рассогласованность которых запускает механизмы адаптационного дистресса, ведущего к прогрессированию морфологической деструкции, дислипидемии, ацеклерации атерогенеза, развитию гемодинамических и гидродинамических нарушений. Препарат Мексидол имеет широкий спектр фармакологической активности, действующий на основные патогенетические звенья первичной открытоугольной глаукомы (ПОУГ). ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить вазоремодулирующее, антиоксидантное и антигипоксантное действие препарата Мексидол у пациентов с ПОУГ. МАТЕРИАЛ И МЕТОДЫ В исследование включено 78 пациентов с ПОУГ начальной стадии (n=43) и развитой стадии (n=35), средний возраст которых составил 67,8±1,5 года; 47 пациентов основной группы дополнительно к местному гипотензивному лечению получали Мексидол, 31 пациент составил группу контроля. В группах сравнения определяли степень ЭД по результатам пробы с реактивной гиперемией, исследовали уровень стабильного метаболита оксида азота (нитрита NO2–) и эндотелина-1 в плазме крови. Общую оценку оксидативного стресса проводили методом высокоэффективной жидкостной хроматографии. Исследования функциональной активности сетчатки проводили с использованием электроретинографа и статической компьютерной периметрии по стандартной методике. РЕЗУЛЬТАТЫ На фоне применения препарата Мексидол у пациентов основной группы значимо повышается индекс осцилляторных потенциалов, снижается межпиковая латентность, наблюдаются положительная динамика периметрических индексов, улучшение функции эндотелия сосудов в пробе с реактивной гиперемией, уменьшение концентрации в плазме крови медиатора-констриктора ЕТ-1, умеренный рост нитрита (NO2–) и уменьшение коэффициента биоэффекторной вазотонической активности, повышается уровень глутатионпероксидазы (p<0,05 по сравнению с исходным значением), снижается содержание малонового диальдегида, улучшается липидный обмен у пациентов основной группы (снижение уровня общего холестерина, холестерина липопротеидов низкой плотности, триглицеридов, снижение индекса атерогенности по сравнению с исходным значением). ЗАКЛЮЧЕНИЕ Препарат Мексидол проявил себя как эффективный эндотелиопротектор, мощный антиоксидант и антигипоксант, способствовал снижению факторов ацеклерации атерогенеза у пациентов с ПОУГ.

6 March 2025 in Russian Annals of Ophthalmology
Verified
Journal Article
Closed access
AVA.S. Vlasova
A.S. Vlasova
SPS.A. Petrov
S.A. Petrov
ERE.V. Renzyak
E.V. Renzyak
TMTatiana Malishevskaya
Tatiana Malishevskaya
Glaucoma is a chronic multifactorial neurodegenerative disease; the most studied local risk factors for glaucoma progression are elevated intraocular pressure (IOP) and its diurnal fluctuations. However, normalization of IOP does not always guarantee stabilization of the glaucomatous process. This article reviews data from international and Russian studies on the pathophysiological mechanisms underlying the development and progression of glaucomatous optic neuropathy, and discusses current approaches to its therapeutic management.